The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Designing clinical trials for high-risk myeloma: innovative strategies and challenges
Hearn Cho, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY, and Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the challenges of designing clinical trials for patients with high-risk multiple myeloma. The panel explores adaptive platform trials, including MMRC Horizon Two (NCT07053436), strategies for introducing immunotherapy earlier, flexible eligibility criteria, and the evolving role of autologous stem cell transplantation and treatment duration. This discussion took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
